<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7118351/results/search/drug/results.xml">
  <result pre="pmid: 31964466 doi: 10.5483/BMBRep.2020.53.3.175BMB-53-166 : Article Antiviral activity of sertindole," exact="raloxifene" post="and ibutamoren against transcription and replication-competent Ebola virus-like particles"/>
  <result pre="adopting GHSR agonists as hit compounds. Antiviral Ebola virus Ibutamoren" exact="Raloxifene" post="Sertindole INTRODUCTION The genus Ebolavirus belonging to the family"/>
  <result pre="GHSR agonists as hit compounds. Antiviral Ebola virus Ibutamoren Raloxifene" exact="Sertindole" post="INTRODUCTION The genus Ebolavirus belonging to the family Filoviridae"/>
  <result pre="previous reports of GPCR modulators as anti-EBOV compounds (19-21). Particularly," exact="sertindole" post="(EC50, 0.7 μM; SI, &amp;gt; 45.8), raloxifene hydrochloride (raloxifene;"/>
  <result pre="compounds (19-21). Particularly, sertindole (EC50, 0.7 μM; SI, &amp;gt; 45.8)," exact="raloxifene" post="hydrochloride (raloxifene; EC50, 0.5 μM; SI, 47.1) and ibutamoren"/>
  <result pre="comparable or superior to the known anti-EBOV compounds such as" exact="ribavirin" post="(RBV) and T-705 in their inhibitory effects. To establish"/>
  <result pre="inhibitory effects. To establish this finding, we purchased highly purified" exact="sertindole" post="(≥ 97.5%), raloxifene (≥ 98%), and ibutamoren (≥ 98%)"/>
  <result pre="establish this finding, we purchased highly purified sertindole (≥ 97.5%)," exact="raloxifene" post="(≥ 98%), and ibutamoren (≥ 98%) and repeated the"/>
  <result pre="minigenome-derived VP40 was downregulated in a dose-dependent manner by sertindole," exact="raloxifene" post="and ibutamoren as well as RBV, a positive control,"/>
  <result pre="spots was reduced significantly in the presence of 10 μM" exact="sertindole" post="(by 84.7%), raloxifene (by 69.1%), or ibutamoren (by 74.2%)"/>
  <result pre="significantly in the presence of 10 μM sertindole (by 84.7%)," exact="raloxifene" post="(by 69.1%), or ibutamoren (by 74.2%) as well as"/>
  <result pre="dose-dependent manner (Fig. 3C). These data strongly suggested that sertindole," exact="raloxifene" post="and ibutamoren not only prevent trVLP-derived EBOV viral replication"/>
  <result pre="the antiviral efficacy of the three active compounds including sertindole," exact="raloxifene" post="and ibutamoren against other human RNA viruses, such as"/>
  <result pre="levels, fat-free mass, and energy expenditure; however, due to increased" exact="cortisol" post="levels, it has yet to be approved by the"/>
  <result pre="(the Korea Chemical Bank) deposited by domestic chemists. Highly purified" exact="sertindole" post="(≥ 97.5%) and ibutamoren (≥ 98%) were purchased from"/>
  <result pre="97.5%) and ibutamoren (≥ 98%) were purchased from Sigma-Aldrich, and" exact="raloxifene" post="(≥ 98%) from Santa Cruz Biotechnology. Control antiviral compounds,"/>
  <result pre="systemAntiviral Res15822623710.1016/j.antiviral.2018.08.01330149038 20FanHDuXZhangJet al.2017Selective inhibition of Ebola entry with selective" exact="estrogen" post="receptor modulators by disrupting the endolysosomal calciumSci Rep74122610.1038/srep4122628117364 21ChengHLear-RooneyCMJohansenLet"/>
  <result pre="microarray analysisBMC Genomics121410.1186/1471-2164-12-1421214938 25JungENamSOhHet al.2019Neutralization of acidic intracellular vesicles by" exact="niclosamide" post="inhibits multiple steps of the dengue virus life cycle"/>
  <result pre="the trVLP system in the presence of increasing concentrations of" exact="sertindole" post="(A), raloxifene (B) or ibutamoren (C) using RBV (D)"/>
  <result pre="system in the presence of increasing concentrations of sertindole (A)," exact="raloxifene" post="(B) or ibutamoren (C) using RBV (D) as a"/>
  <result pre="μM RBV, or 10 μM of each hit compound (sertindole," exact="raloxifene" post="or ibutamoren). On day 1 p.i., cells were fixed"/>
  <result pre="± 0.0 &amp;gt; 30.0 &amp;gt; 37.1 Histamine H1-receptor antagonist 2" exact="Loperamide" post="2.0 ± 1.3 &amp;gt; 30.0 &amp;gt; 18.6 Opioid receptor"/>
  <result pre="± 2.1 26.9 ± 18.1 Histamine H2 receptor inhibitor 4" exact="Benztropine" post="mesylate 3.1 ± 1.4 &amp;gt; 30.0 &amp;gt; 10.9 Muscarinic"/>
  <result pre="Benztropine mesylate 3.1 ± 1.4 &amp;gt; 30.0 &amp;gt; 10.9 Muscarinic" exact="acetylcholine" post="M1 receptor antagonist 5 Sertindole 0.7 ± 0.4 &amp;gt;"/>
  <result pre="&amp;gt; 30.0 &amp;gt; 10.9 Muscarinic acetylcholine M1 receptor antagonist 5" exact="Sertindole" post="0.7 ± 0.4 &amp;gt; 30.0 &amp;gt; 45.8 Dopamine D2"/>
  <result pre="antagonist 5 Sertindole 0.7 ± 0.4 &amp;gt; 30.0 &amp;gt; 45.8" exact="Dopamine" post="D2 receptor inhibitor, serotonine 5-HT receptor inverse agonist 6"/>
  <result pre="agonist 6 3-CPMTd 1.3 ± 0.5 &amp;gt; 30.0 &amp;gt; 26.3" exact="Dopamine" post="transporter inhibitor 7 Chlorcyclizine 2.7 ± 2.2 &amp;gt; 30.0"/>
  <result pre="± 0.5 &amp;gt; 30.0 &amp;gt; 26.3 Dopamine transporter inhibitor 7" exact="Chlorcyclizine" post="2.7 ± 2.2 &amp;gt; 30.0 &amp;gt; 17.0 Histamine H1"/>
  <result pre="antagonist 9 Triflupromazine 1.4 ± 0.5 &amp;gt; 30.0 &amp;gt; 23.8" exact="Dopamine" post="D1, D2 receptor antagonist 10 Raloxifene 0.5 ± 0.0"/>
  <result pre="&amp;gt; 30.0 &amp;gt; 23.8 Dopamine D1, D2 receptor antagonist 10" exact="Raloxifene" post="0.5 ± 0.0 25.6 ± 0.2 47.1 ± 2.2"/>
  <result pre="0.5 ± 0.0 25.6 ± 0.2 47.1 ± 2.2 Selective" exact="estrogen" post="receptor modulator 11 Proadifen 2.7 ± 0.7 &amp;gt; 30.0"/>
  <result pre="&amp;gt; 30.0 &amp;gt; 11.6 Cytochrome P450 inhibitor, Ca antagonist 12" exact="Perphenazine" post="0.7 ± 0.2 17.4 ± 0.6 27.7 ± 9.2"/>
  <result pre="0.7 ± 0.2 17.4 ± 0.6 27.7 ± 9.2 Postsynaptic" exact="dopamine" post="2 receptor inhibitor 13 Ibutamoren mesylate &amp;lt; 0.4 &amp;gt;"/>
  <result pre="Piperacetazine 2.0 ± 0.6 26.1 ± 5.5 15.7 ± 4.6" exact="Dopamine" post="receptor antagonist 15 SU11274 2.6 ± 1.4 &amp;gt; 30.0"/>
 </snippets>
</snippetsTree>
